In a new study, an experimental obesity drug from Novo Nordisk, CagriSema allowed people to lose more than 20% of their body weight, on average, a result that caused the Danish company's stock price to fall by as much as 29%. Yes, fall. For anyone not following the heated race for obesity drug dominance, it may look like we're living upside-down. After all, if this data were unveiled three years ago, the market reaction would have been wildly different. The stock might have gone up and headlines would have heralded an advance in the fight against obesity. But we're in a new era of obesity medicine. The bar for success, once modest, has soared—especially so for CagriSema. Let me explain.
Though Novo will make mind-blowing money from its existing obesity drugs in the coming years (its GLP-1 drugs are likely to become pharma's most lucrative franchise next year), CagriSema was seen as essential for continued growth in 2030 and beyond. And the study suggests it may not be the contender investors had hoped for.
この記事は Mint Chennai の January 02, 2025 版に掲載されています。
7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、9,000 以上の雑誌や新聞にアクセスしてください。
すでに購読者です ? サインイン
この記事は Mint Chennai の January 02, 2025 版に掲載されています。
7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、9,000 以上の雑誌や新聞にアクセスしてください。
すでに購読者です? サインイン
Nayara Energy to make buyback offer
Nayara Energy, India's biggest private fuel retailer, will make an offer to minority shareholders to buy back 25.9 million outstanding shares at ₹731 apiece, the firm said.
CorporatEdge bags ₹100 cr equity fund
CorporatEdge, which provides flexible workspaces to companies, has raised ₹100 crore from private equity firm Carpediem Capital for expansion of its business.
Stock market pandemonium: will history repeat itself?
Reversal now?
RE sector hit by weak demand, cancelled projects
India's renewable energy sector is facing obstacles including weak demand for tenders, power agreement delays and project cancellations, the Institute for Energy Economics and Financial Analysis said on Thursday.
PM Mudra Yojana disbursed ₹31.85 trillion since inception
The Centre has disbursed ₹31.85 trillion of the ₹32.61 trillion allocated under the Pradhan Mantri Mudra Yojana (PMMY) in the nearly 10 years since its launch until February 2025, indicating demand for credit among micro and small businesses, two people aware of the matter told Mint.
No US Tariffs on Mexican Goods Part of Trade Deal for a Month
U.S. President Donald Trump on Thursday said Mexico won't be required to pay tariffs on any goods that fall under the United States-Mexico-Canada Agreement (USMCA) on trade until April 2, but made no mention of a reprieve for Canada despite his commerce secretary saying a comparable exemption was likely.
Assessment of reciprocal tariff hinges on India-US trade talks
For India, safeguarding its interests remains paramount in the negotiations, says FM
Improved growth rate gives govt extra fiscal headroom
Revision in FY25 economic growth to 9.9% allows Centre to have slightly larger fiscal deficit
Britannia's CEO Rajneet Kohli quits
Biscuit maker Britannia Industries said on Thursday that its chief executive officer Rajneet Singh Kohli has resigned after serving two-and-a-half years in the role.
Economy to Grow 6.5% in the Coming Fiscal Year: Crisil
India's economy is set to grow at a steady 6.5% in fiscal 2026, driven by strong domestic demand, despite global headwinds, including geopolitical uncertainties and US-led trade actions, Crisil forecast on Thursday.
